BPC-157 research: what the published literature shows

Three decades of animal data, a thin slice of early human work, and a regulatory picture that is still moving.

TL;DR

• The BPC-157 research base is mostly animal: tendon healing, intestinal damage, and wound models.
• Mechanism work points to angiogenesis (new blood vessel formation) and nitric oxide signaling.
• Large human trials are limited. Anyone reading marketing claims should know the difference between animal and human evidence.

What it is

BPC-157 stands for Body Protective Compound 157. It is a synthetic peptide that copies a 15-amino-acid stretch of a protein found in human stomach juice. Most of the published research has been led by Predrag Sikiric's group in Croatia, and the literature now spans more than thirty years (Sikiric et al., Current Pharmaceutical Design, 2014).

How it works

The proposed mechanism, in plain English: BPC-157 appears to help the body build new small blood vessels and direct repair cells to the right place. The technical names are angiogenesis and nitric oxide signaling. Picture a road crew at a pothole — new supply lines and active dispatchers. Animal studies have linked BPC-157 to both jobs (Gwyer et al., Cell and Tissue Research, 2019).

Who asks about it

People usually arrive at BPC-157 from a recovery, gut-health, or sports-medicine context. The questions that follow are practical: what has been studied, in what species, and how well does the evidence hold up? That is what this post answers.

What the research says

The animal literature covers several recurring themes. Tendon-to-bone healing in rats. Intestinal damage and colitis-like models. Brain-gut signaling work, often using the vagus nerve as a path. Wound healing and bone repair models. Across these settings, the mechanism story is consistent: angiogenesis, nitric oxide signaling, and faster recovery in the treated animals (Gwyer et al., 2019).

Human research is much thinner. There are early-phase safety reports and small pilot studies in the literature, but no large randomized controlled trials. That is the honest line.

What to know before considering it

As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. Any physician conversation about BPC-157 has to start with the regulatory reality. Side effects in the available human literature appear limited, but the human sample size is small.

The Halftime POV

There is a real research base here, and there is also a wide gap between what has been shown in rodents and what has been shown in people. We treat both as true at the same time. When the human evidence improves — or the regulatory picture changes — we will say so without dressing it up.

---

Related reading:

• BPC-157: what this body protection compound is
• How BPC-157 promotes tissue repair: the mechanism
• BPC-157 human trials: what has actually been studied

---

FAQ

Q: What has BPC-157 been studied for? A: Most of the published BPC-157 work is in animals. Studies cover tendon healing, intestinal damage models, brain-gut signaling, and wound healing. Human clinical trial data is limited.

Q: Is there human research on BPC-157? A: There are a small number of early human safety and pilot studies in the published literature, but no large randomized trials. The honest line is that the evidence base is mostly animal-driven.

Q: Is BPC-157 FDA-approved? A: No. BPC-157 is not FDA-approved. As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.

---

Disclaimer

As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157. Current Pharmaceutical Design, 2014.
• Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019.

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.